000			02101nam a22003615i 4500
001			76207
003			ES-MaUEC
005			20230202101941.0
007			cr nn 008mamaa
008			131107s2014 gw a s 001 0 eng d
020			_a9783319009780
024	7		_a10.1007/978-3-319-00978-0 _2doi
040			_aES-MaUEC
050		4	_aRM281 _b.M65 2014 EB
082	0	4	_a615.372
245	0	0	_aMolecular Vaccines _cedited by Matthias Giese
264		1	_aCham, Switzerland _bSpringer International Publishing International Publishing _c2014
300			_a1 recurso en línea (XXVIII, 870 páginas) _b98 ilustraciones, 74 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	2		_gVolumen 2 . _tFrom Prophylaxis to Therapy
520	3		_aThis title discusses all aspects of non-infectious and non-cancer- so called NINC - vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aVacunas _0comprobar BNE19900984775 _2embne _9140409
700	1		_aGiese, Matthias _0n 2016185666 _eeditor literario _948620
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-00978-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319009780
907			_a.b12818252 _b14-11-17 _c01-10-14
998			_am _a_alco _a_vill _b14-11-17 _cm _dz _ea _feng _ggw _h0
945			_aRM281 .M65 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11547479 _z06-04-17
999			_c76207 _d76207 _x1